Royalty Pharma hikes dividend by 4.8%
Royalty Pharma PLC (RPRX) has announced a 4.8% dividend hike to $0.22 quarterly per share for 2025. This marks the 5th consecutive year of increased dividends by RPRX.
The new dividend will be paid on March 10, 2025 to shareholders of record at the close of business on February 21, 2025. The dividend yield for RPRX is 3% at a stock price of $29.50. Last year the company announced a dividend hike of 5.0%.
The 5 year CAGR for the RPRX dividend is exactly 8.0% with the company now paying an estimated annual dividend of $518 million.
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma became publicly listed on June 16, 2020.
